Patients diagnosed with clinical stage I (CS I) nonseminomatous germ cell tumors (NSGCT) have excellent survival. There are several therapies that contribute to this outcome and choosing among them can be challenging for both patient and physician. A decision tree analytical approach has been proposed, which incorporates quality of life outcomes and survival data to quantitatively determine the optimal approach for individual patients with CS I NSGCT.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Westermann, D. H. & Studer, U. E. High-risk clinical stage I nonseminomatous germ cell tumors: the case for chemotherapy. World J. Urol. 27, 455–461 (2009).
Divrik, R. T., Akdogan, B., Ozen, H. & Zorlu, F. Outcomes of surveillance protocol of clinical stage I nonseminomatous germ cell tumors—is shift to risk adapted policy justified? J. Urol. 176, 1424–1429 (2006).
Read, G. et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J. Clin. Oncol. 10, 1762–1768 (1992).
Böhlen, D., Borner, M., Sonntag, R. W., Fey, M. F. & Studer, U. E. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. J. Urol. 161, 1148–1152 (1999).
Stephenson, A. J. et al. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. J. Clin. Oncol. 23, 2781–2788 (2005).
Morash, C. & Cagiannos, I. High-risk clinical stage I NSGCT: the case for RPLND. World J. Urol. 27, 449–453 (2009).
Nguyen, C. T. et al. Defining the optimal treatment for clinical stage I nonseminomatous germ cell testicular cancer using decision analysis. J. Clin. Oncol. 28, 119–125 (2010).
Beck, S. D., Peterson, M. D., Bihrle, R., Donohue, J. P. & Foster, R. S. Short-term morbidity of primary retroperitoneal lymph node dissection in a contemporary group of patients. J. Urol. 178, 504–506 (2007).
Williams, S. B. et al. Morbidity of open retroperitoneal lymph node dissection for testicular cancer: contemporary perioperative data. BJU Int. 105, 918–921 (2009).
Tarin, T. V., Sonn, G. & Shinghal, R. Estimating the risk of cancer associated with imaging related radiation during surveillance for stage I testicular cancer using computerized tomography. J. Urol. 181, 627–632 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Roy, O., Kavoussi, L. Decision tree model has potential to improve NSGCT management. Nat Rev Urol 7, 308–310 (2010). https://doi.org/10.1038/nrurol.2010.62
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2010.62
